1. Home
  2. RCUS vs EYE Comparison

RCUS vs EYE Comparison

Compare RCUS & EYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • EYE
  • Stock Information
  • Founded
  • RCUS 2015
  • EYE 1990
  • Country
  • RCUS United States
  • EYE United States
  • Employees
  • RCUS N/A
  • EYE N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • EYE Ophthalmic Goods
  • Sector
  • RCUS Health Care
  • EYE Health Care
  • Exchange
  • RCUS Nasdaq
  • EYE Nasdaq
  • Market Cap
  • RCUS 906.4M
  • EYE 900.5M
  • IPO Year
  • RCUS 2018
  • EYE 2017
  • Fundamental
  • Price
  • RCUS $8.92
  • EYE $19.81
  • Analyst Decision
  • RCUS Buy
  • EYE Buy
  • Analyst Count
  • RCUS 11
  • EYE 8
  • Target Price
  • RCUS $25.33
  • EYE $17.75
  • AVG Volume (30 Days)
  • RCUS 1.2M
  • EYE 3.5M
  • Earning Date
  • RCUS 05-06-2025
  • EYE 05-07-2025
  • Dividend Yield
  • RCUS N/A
  • EYE N/A
  • EPS Growth
  • RCUS N/A
  • EYE N/A
  • EPS
  • RCUS N/A
  • EYE N/A
  • Revenue
  • RCUS $141,000,000.00
  • EYE $1,850,850,000.00
  • Revenue This Year
  • RCUS N/A
  • EYE $7.11
  • Revenue Next Year
  • RCUS $29.83
  • EYE $3.17
  • P/E Ratio
  • RCUS N/A
  • EYE N/A
  • Revenue Growth
  • RCUS N/A
  • EYE 4.31
  • 52 Week Low
  • RCUS $6.50
  • EYE $9.56
  • 52 Week High
  • RCUS $18.98
  • EYE $20.16
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 53.03
  • EYE 79.07
  • Support Level
  • RCUS $8.42
  • EYE $18.85
  • Resistance Level
  • RCUS $9.61
  • EYE $20.16
  • Average True Range (ATR)
  • RCUS 0.49
  • EYE 0.61
  • MACD
  • RCUS 0.06
  • EYE -0.01
  • Stochastic Oscillator
  • RCUS 48.89
  • EYE 84.10

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About EYE National Vision Holdings Inc.

National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.

Share on Social Networks: